.
MergerLinks Header Logo

Announced

Completed

Zura Bio went public via a SPAC merger with JATT Acquisition in a $215m deal.

Financials

Edit Data
Transaction Value£175m
Consideration TypeCash
Capital Owned-
Capital Bid For100%
EV/Sales-
EV/EBITDA-
Share Price Premium-
One Off Charge-

Synopsis

Edit

Zura Bio, a clinical-stage biotechnology company, went public via a SPAC merger with JATT Acquisition, a special purpose acquisition company, in a $215m deal. “This is an important milestone for our company and investors. I am eager to work alongside the proven and experienced leadership at Zura Bio as we collectively build the next immunology leader. This transaction allows us to progress our multi-asset pipeline targeting important immunology pathways, including IL7, TSLP and IL33, with best-in-class potential to help patients in need of new therapies,” Someit Sidhu, Zura Bio CEO.

© COPYRIGHT 2024 MERGERLINKS LIMITED.

ALL RIGHTS RESERVED.

15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.

CONTACT US